Aerosolized prostacyclin for acute lung injury (ALI) and acute respiratory distress syndrome (ARDS)

Added April 22, 2013

Read the full article

There is no current evidence to support or refute the routine use of aerosolized prostacyclin for patients with acute lung injury (ALI) and acute respiratory distress (ARDS).

ALI and ARDS are critical conditions that are associated with high mortality and morbidity. Aerosolised prostacyclin has been used to improve oxygenation despite the limited evidence available so far. This review assesses the benefits and harms of aerosolised prostacyclin in critically ill patients with acute lung injury and acute respiratory distress syndrome.

Share